NCT04120259

Brief Summary

'This study aims to compare the effect of Metformin alone vs Metformin plus Apple Cider Vinegar in newly diagnosed Type 2 Diabetic Patients

Trial Health

87
On Track

Trial Health Score

Automated assessment based on enrollment pace, timeline, and geographic reach

Enrollment
126

participants targeted

Target at P50-P75 for not_applicable diabetes-mellitus-type-2

Timeline
Completed

Started Apr 2019

Shorter than P25 for not_applicable diabetes-mellitus-type-2

Geographic Reach
1 country

1 active site

Status
completed

Health score is calculated from publicly available data and should be used for screening purposes only.

Trial Relationships

Click on a node to explore related trials.

Study Timeline

Key milestones and dates

Study Start

First participant enrolled

April 22, 2019

Completed
4 months until next milestone

Primary Completion

Last participant's last visit for primary outcome

August 26, 2019

Completed
Same day until next milestone

Study Completion

Last participant's last visit for all outcomes

August 26, 2019

Completed
1 month until next milestone

First Submitted

Initial submission to the registry

October 7, 2019

Completed
2 days until next milestone

First Posted

Study publicly available on registry

October 9, 2019

Completed
Last Updated

October 21, 2019

Status Verified

October 1, 2019

Enrollment Period

4 months

First QC Date

October 7, 2019

Last Update Submit

October 17, 2019

Conditions

Outcome Measures

Primary Outcomes (3)

  • BMI (Anthropometric Measurement)

    Body Mass Index: A measure of obesity calculated as weight in kilograms divided by height in meters square

    12 weeks

  • Measurement of Hemoglobin A1c

    A blood test for Glycated Hemoglobin that represents a 2-3 month glycemic control

    12 weeks

  • Measurement of Fasting Blood Sugar

    A blood test that involves the measurement of plasma glucose after 8 to 12 hours of fasting

    12 weeks

Study Arms (2)

Group 1

ACTIVE COMPARATOR

Intervention: Metformin Tablet oral 750 mg OD

Drug: Metformin Oral Tablet

Group 2

EXPERIMENTAL

Intervention: Metformin 750 mg oral plus 2 tablespoons of apple cider vinegar OD

Drug: Metformin Oral TabletDietary Supplement: Vinegar

Interventions

A biguanide drug used as a first line therapy for Diabetes MellitusType 2

Group 1Group 2
VinegarDIETARY_SUPPLEMENT

A common herbal/dietary supplement used for centuries as an anti bacterial, cleaning,cooking, anti diabetic agent, to name a few uses.

Group 2

Eligibility Criteria

Age18 Years - 65 Years
Sexall
Healthy VolunteersNo
Age GroupsAdult (18-64), Older Adult (65+)

You may qualify if:

  • Recently diagnosed Type 2 diabetic patients taking metformin 750 mg daily as the oral antidiabetic agent
  • Patients with Hemoglobin A1c in the range of 6.5 to 7.5%

You may not qualify if:

  • All newly diagnosed Diabetic Patients requiring a dosage other than 750 mg per day
  • Patients on Insulin Therapy or any drugs for diabetes other than Metformin
  • Pregnant and Lactating women
  • Patients with food allergies to either apple or any source of vinegar
  • Patients unable to communicate efficiently\\mentally challenged
  • Type 2 Diabetic patients with any of the complications of long standing uncontrolled diabetes

Contact the study team to confirm eligibility.

Sponsors & Collaborators

Study Sites (1)

Ziauddin University

Karachi, Sindh, 7500, Pakistan

Location

MeSH Terms

Conditions

Diabetes Mellitus, Type 2

Interventions

MetforminAcetic Acid

Condition Hierarchy (Ancestors)

Diabetes MellitusGlucose Metabolism DisordersMetabolic DiseasesNutritional and Metabolic DiseasesEndocrine System Diseases

Intervention Hierarchy (Ancestors)

BiguanidesGuanidinesAmidinesOrganic ChemicalsAcetatesAcids, AcyclicCarboxylic AcidsFatty Acids, VolatileFatty AcidsLipids

Study Officials

  • Dr Momina Abid, MBBS,M Phil (ongoing)

    Ziauddin University

    PRINCIPAL INVESTIGATOR
  • Dr Zahida Memon, MBBS,M Phil,PhD

    Ziauddin University

    PRINCIPAL INVESTIGATOR

Study Design

Study Type
interventional
Phase
not applicable
Allocation
RANDOMIZED
Masking
NONE
Purpose
TREATMENT
Intervention Model
PARALLEL
Sponsor Type
OTHER
Responsible Party
PRINCIPAL INVESTIGATOR
PI Title
Dr Momina Abid

Study Record Dates

First Submitted

October 7, 2019

First Posted

October 9, 2019

Study Start

April 22, 2019

Primary Completion

August 26, 2019

Study Completion

August 26, 2019

Last Updated

October 21, 2019

Record last verified: 2019-10

Data Sharing

IPD Sharing
Will not share

Locations